Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1070644 | 0.86 | SCN9A (0.65) | SCN9ASMN1; SMN2ALDH1A1MAOBMAOA | |
| SCHEMBL1070481 | 0.84 | SLC6A4 (0.54) | SCN9AMAOBMAOA | |
| SCHEMBL3294896 | 0.84 | SLC6A4 (0.54) | SCN9AMAOBMAOA | |
| SCHEMBL8755190 | 0.81 | RAB9A (0.59) | SCN9ASMN1; SMN2ALDH1A1MAOBMAOA | |
| SCHEMBL8805907 | 0.80 | NPC1 (0.53) | SCN9AALDH1A1MAOBMAOALMNA | |
| SCHEMBL2184473 | 0.80 | MAOB (0.48) | SCN9AMAOBMAOAKMT2A | |
| SCHEMBL2186343 | 0.79 | SCN9A (0.75) | SCN9AMAOBMAOA | |
| SCHEMBL2187391 | 0.79 | SCN9A (0.75) | SCN9AMAOBMAOA | |
| SCHEMBL966440 | 0.79 | SCN9A (0.75) | SCN9AMAOBMAOA | |
| SCHEMBL17666267 | 0.76 | SCN9A (0.49) | SCN9AMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741957-B2 | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2014-06-03 | — | — | US | claimed |
| EP-2977046-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | Newron Pharmaceuticals S.p.A. (IT) | 2016-01-27 | — | — | EP | disclosed |
| US-8741957-B2 | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2014-06-03 | — | — | US | disclosed |
| EP-2343064-A1 | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | Newron Pharmaceuticals S.p.A. (IT) | 2011-07-13 | — | — | EP | disclosed |
| US-20100016437-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-01-21 | — | — | US | disclosed |
| EP-2029130-A2 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | Newron Pharmaceuticals S.p.A. (IT) | 2009-03-04 | — | — | EP | disclosed |
| EP-1870097-A1 | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | Newron Pharmaceuticals S.p.A. (IT) | 2007-12-26 | — | — | EP | disclosed |
| WO-2007144153-A2 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016437-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | PSEN1, MAPT, AADAT | SCN9A 3223/4885SMN1; SMN2 201/4885ALDH1A1 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.